Multislice computed tomography (MSCT) is an additional potential tool for the assessment of coronary artery disease. It can provide information about stenoses in coronary arteries and coronary artery bypass grafts, ventricular size and function, cardiac structure and masses, pulmonary vein anatomy, myocardial perfusion and coronary artery plaque. In this review the recent developments in CT technology that have made cardiac imaging possible are examined and the benefits of the latest 64-slice and dual-source CT scanners explained. Information on how to perform cardiac CT and evidence for its various clinical applications are given. Problems and limitations of cardiac CT and the radiation dose are discussed. Future developments and the likely impact of this rapidly evolving technique on clinical cardiology are considered.

The clinical application of cardiac CT is increasing, but heart rate control is often required to prevent motion artefact. Here, we describe a protocol for heart rate control in patients undergoing outpatient CT coronary angiography (CTCA). Among 121 consecutive patients, 75 (61.9%) with a resting heart rate >60 beats per minute (bpm) required rate control medication. Our protocol called for oral metoprolol 100 mg to be given 60 min before scanning, with patients for whom beta-blockers were contraindicated receiving 240 mg oral verapamil. Additional 5 mg intravenous boluses (maximum for both drugs, 15 mg) were given if the heart rate remained >60 bpm prior to scanning. Of 71 patients treated with oral metoprolol, 59 (83%) achieved a rate 70 bpm at the time of scanning. No adverse events resulted from rate control medication. Image quality was closely related to heart rate. Severe motion artefact (Grade 3) occurred in only 0.9% of patients with a rate 70 bpm. In conclusion, the administration of oral metoprolol according to the described protocol is a safe and effective way of reducing heart rate and improving scan quality in the majority of patients undergoing CTCA.

We report the case of a very late erosion of an Amplatzer septal occluder (ASO) device more than 8 years after implant, presenting without signs of cardiac tamponade. To date, this case represents the longest period between ASO device implantation and clinical presentation following erosion. The overall rate of device erosion remains low, and the majority reported so far has occurred early, but clinicians should remain alert to the possibility of very late erosion in patients with ASO devices.

No abstract